Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
University of Nova Gorica
University
Study
Research
Repository of University of Nova Gorica
About
Search
Browse
Statistics
Login
Show document
A+
|
A-
|
|
SLO
|
ENG
Title:
Frnikola je padla
Authors:
ID
Pregelj, Barbara
(Copyright holder)
ID
Pregelj, Barbara
, UNG (Author)
Files:
This document has no files that are freely available to the public. This document may have a physical copy in the library of the organization, check the status via
COBISS.
Language:
Slovenian
Work type:
Not categorized
Typology:
1.17 - Independent Professional Component Part or a Chapter in a Monograph
Organization:
UNG - University of Nova Gorica
Keywords:
Juan José Millás
,
mladinska književnost
,
prevodi
,
španska mladinska književnost
,
večnaslovniškost
Publication status:
Published
Year of publishing:
2019
Number of pages:
85-96
PID:
20.500.12556/RUNG-4497-932f16cf-9cf2-1352-ac01-8295a68eaf19
COBISS.SI-ID:
5380347
NUK URN:
URN:SI:UNG:REP:TASBSXE2
Publication date in RUNG:
06.05.2019
Views:
4499
Downloads:
0
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
PREGELJ, Barbara, 2019, Frnikola je padla. In :
Juan José Millás, Moja resnična zgodba
[online]. Medvode. p. 85–96. P. 85–96. [Accessed 28 April 2025]. Retrieved from: https://repozitorij.ung.si/IzpisGradiva.php?lang=eng&id=4497
Copy citation
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:
Voting is allowed only for
logged in
users.
Share:
Similar works from our repository:
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
Similar works from other repositories:
Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
Preverjanje porekla pri ovcah z uporabo molekularnih genetskih označevalcev
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Record is a part of a monograph
Title:
Juan José Millás, Moja resnična zgodba
Editors:
Barbara Pregelj
Place of publishing:
Medvode
Publisher:
Malinc
Year of publishing:
2019
ISBN:
978-961-6886-64-2
Back